Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Jan 26;90(2):403-7.
doi: 10.1038/sj.bjc.6601586.

Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study

H Mahteme  1 , J Hansson, A Berglund, L Påhlman, B Glimelius, P Nygren, W Graf
Affiliations
Clinical Trial

Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study

H Mahteme et al. Br J Cancer. .

Abstract

Patients with peritoneal or local metastases from colorectal cancer have a poor prognosis. However, aggressive treatments by debulking surgery and infusional intraperitoneal (i.p.) chemotherapy have been tried and appear to benefit selected patients. We assayed the effects of debulking surgery and i.p. chemotherapy with respect to survival and compared the results with matched control patients treated by intravenous (i.v.) chemotherapy. In all, 18 patients with peritoneal and/or local metastases from colorectal adenocarcinoma underwent debulking surgery followed by 5-fluorouracil (5-FU) 550 mg m(-2) day(-1) i.p. and leucovorin (LV) 60 mg m(-2) day(-1) i.v. The chemotherapy was started the day after surgery and was given daily for 6 days and repeated monthly for totally eight courses. The control patients, matched for age, gender, performance status and metastatic site, were randomly selected from controlled clinical chemotherapy trials and treated with i.v. 5-FU+LV or i.v. methotrexate+5-FU+LV. There was no treatment-related mortality. The median survival among i.p. patients was 32 months compared to 14 months in the control group. In all, 11 patients who underwent macroscopically radical surgery had a longer survival than those who were not radically operated (P=0.02). These results indicate that patients with peritoneal metastases and/or locally advanced cancers but without distant metastases may benefit from cytoreductive surgery combined with i.p. chemotherapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative proportion surviving (Kaplan–Meier).
Figure 2
Figure 2
Cumulative proportion surviving (Kaplan–Meier).
See this image and copyright information in PMC

References

    1. Assersohn L, Norman A, Cunningham D, Benepal T, Ross PJ, Oates J. Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. Br J Cancer 1999; 79: 1800–1805 - PMC - PubMed
    1. Beaujard A, Glehen O, Caillot J, Francois Y, Bienvenu J, Panteix G, Garbit F, Grandclement E, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 2000; 88: 2512–2519 - PubMed
    1. Cavaliere F, Di Flippo F, Botti C, Cosimelli M, Giannarelli D, Aloe L, Arcuri E, Aromatario C, Consolo S, Callopoli A, Laurenzi L, Tedesco M, Di Angelo P, Giunta S, Cavaliere R. Peritonectomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis. Eur J Surg Oncol 2000; 26: 486–491 - PubMed
    1. Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000; 321: 531–551 - PMC - PubMed
    1. Csoka K, Larsson R, Tholander B, Gerdin E, dela Torre M, Nygren P. Cytotoxic drug sensitivity testing of tumour cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol 1994; 54: 163–170 - PubMed

Publication types

MeSH terms